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Genome-wide DNA methylation profiles in
progression to in situ and invasive carcinoma of
the breast with impact on gene transcription and
prognosis
Thomas Fleischer1,2, Arnoldo Frigessi3, Kevin C Johnson4,5, Hege Edvardsen1, Nizar Touleimat6, Jovana Klajic1,2,7,
Margit LH Riis7,8,9, Vilde D Haakensen1,2, Fredrik Wärnberg10, Bjørn Naume11, Åslaug Helland1,11,
Anne-Lise Børresen-Dale1,2, Jörg Tost6, Brock C Christensen4,5 and Vessela N Kristensen1,2,7*

Abstract
Background: Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive breast carcinoma. DNA
methylation alterations are thought to be an early event in progression of cancer, and may prove valuable as a tool
in clinical decision making and for understanding neoplastic development.
Results: We generate genome-wide DNA methylation profiles of 285 breast tissue samples representing progression of
cancer, and validate methylation changes between normal and DCIS in an independent dataset of 15 normal and 40
DCIS samples. We also validate a prognostic signature on 583 breast cancer samples from The Cancer Genome Atlas.
Our analysis reveals that DNA methylation profiles of DCIS are radically altered compared to normal breast tissue,
involving more than 5,000 genes. Changes between DCIS and invasive breast carcinoma involve around 1,000 genes.
In tumors, DNA methylation is associated with gene expression of almost 3,000 genes, including both negative and
positive correlations. A prognostic signature based on methylation level of 18 CpGs is associated with survival of breast
cancer patients with invasive tumors, as well as with survival of patients with DCIS and mixed lesions of DCIS and
invasive breast carcinoma.
Conclusions: This work demonstrates that changes in the epigenome occur early in the neoplastic progression,
provides evidence for the possible utilization of DNA methylation-based markers of progression in the clinic, and
highlights the importance of epigenetic changes in carcinogenesis.

Background
Epigenetic marks (and DNA methylation in particular)
are known to be deregulated in cancer. Cancer-specific
changes include hypermethylation of CpGs in gene promoters [1], hypomethylation of non-CpG island CpGs
[2], and overall increase in variation of methylation [3,4].
DNA methylation patterns are also associated with histopathological parameters such as hormone receptor status,
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TP53 mutation status, histologic grade, stage, and survival
time [5-9].
Ductal carcinoma in situ (DCIS) of the breast is a neoplasm where the cells are confined by the basement membrane of breast ducts. DCIS is a precursor of an invasive
breast carcinoma (IBC). Treatment of DCIS consists of
surgical excision in the form of either breast-conserving
surgery (that is, wide local resection or sector resection) or
removal of the entire breast parenchyma (mastectomy).
Treatment by mastectomy results in very few recurrences
but is considered over-treatment in a majority of cases. Approximately 30% of patients treated by breast-conserving
surgery alone are reported to develop a local recurrence
after 15 years follow-up and the risk of local recurrence is
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reduced by half if postoperative radiotherapy is given
[10,11]. To avoid overtreatment of patients with DCIS it
would be of great value to be able to predict which patients
have potentially malignant and invasive tumors and are
likely to experience recurrence of disease.
Epigenetic studies of breast tissue report aberrant methylation levels already present in benign neoplastic breast lesions such as columnar cell lesions and ductal hyperplasia
[12,13]. More studies have reported aberrant methylation
levels in DCIS (summarized in [11]). Most of these studies
reported methylation levels of only one or a few genes,
while two studies have used genome-wide approaches.
These studies reported 108 and 214 CpG islands (CGIs),
respectively, to be hypermethylated in DCIS compared
with normal tissue and that these CGIs were enriched for
homeobox genes [14,15].
Studies of benign or premalignant tumors from a variety
of organs have revealed that some of these lesions have
epigenetic characteristics that separate them both from
normal tissue and from the malignant tumors. These studies include results from meningiomas of the brain [16,17],
gastric lesions [18,19], cystadenomas of the ovary [20],
colorectal lesions [21,22] and uterine leiomyoma [23,24].
Taken together, these data suggest that epigenetic changes
occur early in cancer development and as such have great
potential as biomarkers in addition to increase our biological understanding of progression of cancer.
In this study, we investigate methylation patterns in a
total of 285 fresh frozen tissue samples, including 46
normal breast tissue samples from healthy women, 22
pure DCIS, 31 mixed DCIS-IBC and 186 IBC of stage I
and II. Validation was performed using 583 breast cancer
samples from The Cancer Genome Atlas (TCGA), as
well as in an independent set of DCIS and adjacent normal tissues.
The aim of this study was to investigate DNA methylation patterns during progression of breast cancer. Genomewide profiling allows identification of molecular changes
that occur during neoplasia as well as changes that are
required for a tumor to acquire invasive capabilities. Additionally, the association between methylation and survival
of patients was studied, and a prognostic signature was
identified. The correlation between methylation and expression was incorporated into the analyses. These findings
could improve our understanding of the biological mechanisms that occur during progression of breast cancer, and
contribute to identification of biomarkers for risk-related
classification of patients with in situ and invasive breast
cancer.

Results
Tumor classification based on DNA methylation

Genome-wide DNA methylation analysis was performed
on a total of 239 breast tumor samples and 46 normal
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samples. The tumor samples included 22 pure DCIS, 31
mixed DCIS-IBC and 186 pure IBC. A gene region collapsed data set was constructed to reduce the dimensions of the data and to study the methylation in the
functional regions of the genes. Each gene is represented
by up to six methylation values representing the respective
functional regions as described in Materials and methods).
Hierarchical clustering was performed to explore the
structure of the DNA methylation data, using methylation
levels of the 500 most variable gene regions (Figure 1).
The samples were divided into two main clusters, where
one contained all normal samples as well as tumor samples,
and the other contained only tumor samples. Basal-like tumors were enriched in the cluster containing the normal
samples while luminal A and luminal B tumors were
mostly found in the other cluster. DCIS and mixed DCISIBC tumors were found in both clusters.
Differentially methylated gene regions were identified
between the five intrinsic subtypes of breast cancer. For
a locus to be considered differentially methylated, the
minimum difference between the median methylation
levels in the groups was 0.1 (10%) and the false discovery rate (FDR) q-value was smaller than 0.01 (1%);
16,723 gene regions were differentially methylated between the intrinsic subtypes of breast cancer (listed in
Additional file 1). Hierarchical clustering of the invasive
tumors using these regions confirmed that the basallike and normal-like tumors showed clearly distinct profiles compared with the luminal-like tumors (Additional
file 2).
Correlation between DNA methylation and gene
expression

Correlation between DNA methylation level and gene expression was investigated to assess to what degree gene
expression may be influenced by DNA methylation in
breast cancer. Gene expression level was tested for correlation to both methylation level of single CpGs within
100 kb of a transcription start site (TSS) and methylation
level of gene regions.
Pearson correlation was calculated between gene expression and methylation level of CpGs within 100 kb of
a TSS, and an association was considered significant if
the Bonferroni corrected P-value was smaller than 0.05.
By this definition, the methylation level of 9,800 CpGs
was significantly correlated with the expression of 2,960
genes (Additional file 3). The expression level of 2,558
genes was negatively correlated with the methylation
level of at least one CpG, while the expression level of 852
genes was positively correlated with the methylation level
of at least one CpG. The positive correlations were quite
evenly distributed relative to TSSs (±100 kb; Figure 2A).
The negative correlations were also found at all distances relative to TSSs (±100 kb; Figure 2A), but they

Fleischer et al. Genome Biology 2014, 15:435
http://genomebiology.com/2014/15/8/435

Page 3 of 13

PAM50
Tissue

Figure 1 Hierarchical clustering of the methylation level of the 500 most variable gene regions. Tissue types (green, healthy breast; blue,
DCIS; purple, mixed DCIS-IBC; red, IBC) and PAM50 subtype (dark blue, luminal A; light blue, luminal B; pink, HER2-enriched; red, basal-like; green,
normal-like) are indicated.

were found to be enriched close to TSSs (1,000 bp upstream to 5,000 bp downstream). The CpGs that correlated with expression were distributed across the whole
genome, and were enriched on chromosomes 1, 17 and
19 (Figure 2B).

A

Pearson correlation was also calculated between gene
expression and the methylation level of each respective
gene region. The expression of 1,719 genes significantly
correlated with methylation level in at least one gene region (Additional file 4). The expression of 1,445 genes

B

Figure 2 CpGs whose methylation level significantly correlated with gene expression (Bonferroni corrected P-value <0.05).
(A) Significance level of correlation between methylation level and gene expression plotted against distance between the CpG and transcription
start site (TSS). Red dots represent negative correlation and blue dots represent positive correlation. (B) Significance level and genome-wide
distribution of correlation between methylation level and gene expression.
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negatively correlated with the methylation level of at
least one gene region, and the expression of 355 genes
positively correlated with the methylation level of at
least one gene region (Figure 3). Of the negative correlations between methylation and expression, almost 40%
were found upstream of TSSs (TSS1500 and TSS200
subregions), while only about 15% of the positive correlations were found upstream of a TSS. The rest of the
negative correlations were distributed in the 5’ UTR,
first exon and gene body, while less than 10% of the
negative correlations were found in the 3’ UTR. Of the
positive correlations, 40% were found in the gene body
and 30% were found in the 3’ UTR, meaning that more
than 70% of positive correlations were found outside of
promoter regions.
Methylation changes during progression of breast cancer

To identify differentially methylated CpGs during progression of breast cancer, Significance Analysis of Microarrays (SAM) was applied to the complete methylation
data set with all CpGs. For a locus to be considered differentially methylated, the difference between the median methylation levels in the two groups had to be at
least 0.1 (10%) and the FDR q-value had to be smaller
100 %

90 %

80 %

70 %

60 %

3'UTR
Gene body
1st exon

50 %

5'UTR
TSS200

40 %

TSS1500

than 0.01 (1%). The differences in methylation levels between normal tissue and DCIS were substantial. A high
degree of CpG methylation deregulation during neoplastic
transformation may have important implications for a better understanding of breast cancer progression. Thus, to
identify the most biologically relevant alterations we examined differences between normal tissue and DCIS in two
independent patient cohorts. Only the significant CpGs or
regions that were differentially methylated in both datasets
are reported. Comparing normal tissue and DCIS revealed
that 16,949 CpGs were differentially methylated, representing 5,659 genes. Comparing DCIS and IBC revealed
that 2,000 CpGs were differentially methylated. These
CpGs represented 1,076 genes, and 1,745 of the CpGs
were hypermethylated while 255 of the CpGs were
hypomethylated (Table 1). All differentially methylated
CpGs are shown in Additional files 5 and 6.
SAM was also applied to the gene region collapsed
data, and comparing normal tissue and DCIS in the two
independent patient cohorts revealed 1,249 differentially
methylated gene regions representing 1,011 genes. In
comparison, 166 gene regions representing 154 genes
were differentially methylated between DCIS and IBC
(Table 1). All differentially methylated gene regions are
shown in Additional files 7 and 8.
To identify pathways for which the differentially methylated genes between normal tissue and DCIS were
enriched Ingenuity Pathways Analysis was performed.
This analysis was performed on the genes represented
by differentially methylated gene regions rather than single CpGs. The differentially methylated genes between
normal tissue and DCIS approached a significant threshold for an enrichment in the agranulocyte adhesion and
diapedesis pathway (P = 0.053) and the granulocyte adhesion and diapedesis pathway (P = 0.084) (Table 2).
The methylation level of four genes (CPA1, CUL7,
LRRTM2 and POU2AF1) increased both from normal to
DCIS and from DCIS to IBC, while 10 genes (ARSJ, CES8,
FAIM2, GPRC5B, ICAM2, P4HA3, PGLYRP2, PLOD1,
PNMAL2, STAP2) showed a decrease in methylation

30 %

Table 1 Differential DNA methylation during progression
of breast cancer

20 %

Healthy-DCISa DCIS-IDC
10 %

b

0%
Negative correlations

Positive correlations

Figure 3 Significant correlation (Bonferroni corrected
P-value <0.05) between gene expression and methylation
level of gene regions. Bar plot showing the distribution of
negative and positive correlations relative to the functional regions
of genes. The distribution is notably different for the negative
versus positive correlations.

Total differentially methylated CpGs

16,949

Total represented genes

5,659

2,000
1,076

Total differentially methylated gene regionsc 1,249

166

Total represented genes

154

a

1,011

Analysis performed in two independent datasets. Only concordant results in
both datasets are reported. bAll individual CpGs differentially methylated
between normal and DCIS, and between DCIS and IBC. cGene regions
differentially methylated between normal and DCIS, and between DCIS and
IBC. Differential methylation was determined by SAM analysis (FDR q-value <1%
and difference in median of groups >10%).
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Table 2 Ingenuity canonical pathways enriched for
differentially methylated genes (represented by gene
regions) between normal tissue and DCIS
Ingenuity canonical
pathways

Benjamini-Hochberg
corrected P-value

Ratio

Agranulocyte adhesion and
diapedesis

0.05

21/
175

Granulocyte adhesion and
diapedesis

0.08

19/
165

between normal and DCIS, but an increase in methylation from DCIS to IBC.
Survival analysis

To identify CpGs for which methylation level may predict
survival, Lasso regularization was performed. The analysis
was performed using methylation level of single CpGs,
preselected to be correlated with gene expression. A survival signature that consisted of 18 CpGs was identified
(Table 3). The methylation level of these CpGs correlated
with the expression level of 26 genes, including IRF6,
TBX5, CSNK1G2, MACF1, KCTD21 and EPN3 (Table 4).
Of the genes associated with the signature, 15 negatively
correlated with methylation level and 11 positively correlated with methylation level. No canonical pathways were
found significantly enriched among the 26 genes. Of the
Table 3 DNA methylation-based prognostic signature
identified by Lasso
Probe

Coefficient

cg05809947

−0.10

cg12219311

−0.08

cg26466505

−0.07

cg20691428

−0.07

cg20869305

0.09

cg22174844

0.16

cg26225829

−0.13

cg04947065

0.06

cg16575694

−0.09

cg16559598

0.07

cg08729004

−0.09

cg13635578

−0.03

cg13744452

−0.04

cg04817034

−0.02

cg07130508

0.02

cg00226265

−0.04

cg13749939

0.06

cg25817165

0.05

A positive coefficient reflects that a high methylation level is associated with
adverse prognosis. These coefficients are used to classify patients into high
and low risk groups.

genes in the signature, 17 were differentially methylated
between normal and DCIS, and 4 were differentially methylated between DCIS and IBC. The survival signature was
applied to patients with invasive tumors (n = 176) as explained in Materials and methods. The patients segregated
exceptionally well into high- and low-risk groups according to breast cancer-specific survival (hazards ratio (HR) =
13.7, P < 2.2e-16; Figure 4A).
To validate the prognostic value of the discovered signature, the signature was applied to a validation set of
breast cancer patients collected by TCGA (n = 583). The
patients were divided into two groups with significantly
different prognosis (HR = 2.31, P = 6.23e-4; Figure 4B).
The prognostic signature derived from patients with
IBC was then applied to patients with DCIS and mixed
DCIS-IBC tumors (n = 52). The patients were separated
into groups with significantly different prognosis (P =
3.69e-2; Figure 4C). The good prognosis group included
14 pure DCIS and 15 mixed DCIS-IBC, while the bad
prognosis group included 7 pure DCIS and 16 mixed
DCIS-IBC. Comparing prognosis in DCIS versus mixed
DCIS-IBC showed that the patients with mixed lesions
had significantly adverse prognosis. In fact, only one
breast cancer-specific death was observed among the patients with pure DCIS.
Multivariable Cox proportional hazard models were
calculated for the patients in the training set (n = 176) as
well as patients in the TCGA validation (n = 583) adjusting for estrogen receptor (ER) status, TP53 mutation status (only training set), T status, and lymph node status.
Classification by the prognostic signature was significantly associated with survival in both data sets (P <
0.001 and P = 0.008, respectively; Table 5). In addition to
the prognostic signature, lymph node status was significantly associated with survival in the TCGA validation
set. Importantly, combining lymph node status and classification by the prognostic signature provided an even
better segregation of patients (P = 8.26e-5; Figure 4D).
Patients that were both lymph node-negative and had a
low index had the best prognosis, while patients that
were lymph node-positive and had a high index had the
worst prognosis. PAM50 classification was not significant in either of the patient cohorts.

Discussion
Here we report the DNA methylation profiles of a breast
cancer progression series, including normal breast tissue,
DCIS, IBC and mixed lesions. Interestingly, most of the
aberrations in the epigenetic profile were observed already
in the pre-invasive DCIS stage. The affected pathways suggested that many of the changes may not occur in the
tumor, but in infiltrating cells or at least in genes that enable cross-talk to such cells. Also of interest was that
DNA methylation profiles of the basal type of breast
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Table 4 Genes whose expression level correlated with methylation level of CpGs in the survival signature
Gene

Probe

Gene region

P-value (methylation-expression)

Coefficient (methylation-expression)

ACAP3

cg16575694

Other

8.5E-03

−0.5

ALG8

cg04817034

Other

4.8E-02

−2.7

BLZF1

cg08729004

Other

2.6E-02

0.9

C1orf74

cg20869305

Other

5.9E-04

38.7

CBS

cg05809947

Other

5.8E-03

−4.5

CEND1

cg13749939

Other

3.5E-04

1.2

CNDP2

cg25817165

Body

1.2E-05

−1.0

COLEC11

cg04947065

Other

8.7E-03

28.9

CSNK1G2

cg12219311

Other

1.5E-02

−0.6

DIEXF

cg20869305

Other

4.5E-04

32.8

EPN3

cg13635578

Other

3.7E-02

−1.6

FCGRT

cg26225829

Other

3.6E-05

2.8

FKBPL

cg00226265

Other

2.7E-02

−1.7

IRF6

cg20869305

Other

1.4E-03

61.1

KCTD21

cg04817034

Other

1.5E-02

−1.6

LDB1

cg07130508

TSS1500

4.3E-02

5.1

MACF1

cg22174844

Body

4.1E-02

−0.9

ORM1

cg13744452

Body

3.3E-07

−13.4

ORM2

cg13744452

Other

6.6E-08

−15.1

SLC19A2

cg08729004

Other

8.2E-03

3.0

SPAG4

cg26466505

Other

4.3E-02

3.3

TALDO1

cg13749939

Other

1.5E-02

1.5

TBX5

cg16559598

TSS1500

4.3E-02

−0.3

U2AF1

cg05809947

Other

2.9E-07

−2.2

USP35

cg04817034

Body

1.4E-02

−4.0

ZNF259

cg20691428

Other

2.0E-02

−1.2

Gene region reflects where the CpG is located relative to the gene, P-value reflects the strength of the correlation between methylation level and expression, and
the coefficient reflects the direction of the correlation between methylation level and expression.

cancer were more similar to normal tissue than were the
luminal-like tumors. These data suggest that the methylation profiles may be a function of the cell of origin as
much as a marker of progression. We also report a signature comprising DNA methylation levels of 18 CpGs that
was prognostic for breast cancer patients with invasive tumors as well as for patients with DCIS and mixed lesions
of DCIS and IBC. The signature was discovered in a training data set of 176 patients and validated in 583 patients
from the TCGA. In the validation patient group the prognostic signature and lymph node status were complementary, potentially providing valuable information for clinical
decision-making. The patients that were classified with
good prognosis by DNA methylation and additionally
were lymph node-negative might benefit from reduced or
no adjuvant treatment, while patients that were classified
with adverse prognosis by DNA methylation and were
lymph node-positive could potentially benefit from more
aggressive treatment.

A great advantage of DNA methylation is that it is relatively easy to design an assay that may be used in a clinical
setting. DNA methylation can be measured on an absolute
scale (from 0 to 100%), is stable in the cell over time, and
is relatively insensitive to handling in the laboratory. This
work clearly shows the potential of DNA methylationbased signatures for clinical utilization.
With data from two independent cohorts of normal
tissue and DCIS, we report that the DNA methylation
profiles of DCIS were radically changed compared with
normal breast tissue, involving more than 5,000 genes.
One cohort consisted of fresh frozen tissue and normal
controls from healthy women, while the other cohort
consisted of formalin-fixed paraffin-embedded (FFPE)
DCIS samples and matched adjacent normal breast tissue. Thus, the reported changes in methylation levels
across these genes appear to be independent of tissue
preparation and the normal tissue’s proximity to tumor
tissue. Comparably, the changes between DCIS and IBC
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Figure 4 Application of the DNA methylation-based prognostic signature for patients. (A) In the original data (n = 176); (B) in the TCGA
validation (n = 583); (C) with either DCIS or mixed DCIS-IBC (n = 52). (D) Classification with the DNA methylation-based prognostic signature was
complementary to classification by lymph node status.

were more modest, involving around 1,000 genes. These
findings suggest that the epigenome is severely altered in
the early neoplastic setting in the breast. Previous studies of breast cancer progression have also reported early
aberrant DNA methylation in DCIS, but they characterized fewer genes (summarized in [11]). The current
study has the advantage of a high coverage methylation
assay (Illumina HumanMethylation450) and leverages
true normal controls from healthy women. Our observation that extensive epigenetic alterations occur early in
cancer progression has been reported for other cancer

types, including colorectal cancer. For example, studies
using the HumanMethylation450 assay reported that
precancerous adenomas demonstrate heterogeneity similar to invasive tumors, and that aberrant DNA methylation occurs early in colorectal cancer formation [22].
Classification of breast cancer by hierarchical clustering showed that basal-like tumors clustered with the
normal samples in one cluster, and luminal A and luminal B tumor clustered together in the second cluster
(Figure 1). This observation largely recapitulates and extends the results from a previous study [8]. Since DNA
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Table 5 Multivariate Cox proportional hazard analyses
HR

HR 95% confidence interval

P-value

ER status

1.32

0.62-2.84

0.470

TP53 mutation

1.08

0.48-2.45

0.850

Training set

T status (2)

2.14

0.89-5.13

0.088

T status (3 or 4)

1.48

0.47-4.59

0.502

Lymph node status

2.22

0.89-5.51

0.087

Prognostic signature

29.0

9.36-89.9

5.4E-09

0.87

0.49-1.55

0.639

TCGA validation
ER status
T status (2)

0.92

0.47-1.82

0.814

T status (3 or 4)

1.14

0.51-2.54

0.749

Lymph node status

2.13

1.14-3.98

0.018

Prognostic signature

2.09

1.21-3.59

0.008

methylation aberrations occur early in carcinogenesis, it
is possible that DNA methylation changes may play a
role in the development of molecular subtypes of breast
cancer, although it is also possible that the correlation
with methylation is a consequence of subtype. Future
studies are needed to define the mechanistic effects that
DNA methylation and other epigenetic marks may have
on early development of cancer.
DCIS lesions tend to grow slower and show less intertumor heterogeneity than IBC lesions. Consequently, it
would be pertinent to perform subtype-specific analyses of
differences between DCIS and IBC. In the present study,
however, the number of DCIS samples was too few to perform subtype-specific analyses. Future studies should aim
to collect enough DCIS samples to divide both DCIS and
IBC samples into intrinsic subtypes of breast cancer while
including enough samples for statistical analyses. The
inter-sample heterogeneity in the normal samples (mammoplastic reductions and needle biopsies from healthy
women) was low compared with the neoplastic lesions
(Figure 1).
Correlation between DNA methylation and gene expression was found throughout the genome and involved
almost 3,000 genes. CpGs whose methylation level correlated with expression were enriched close to TSSs, but
also found at distances up to 100 kb from them. Interestingly, about a quarter of the genes whose expression
level correlated with methylation level showed a positive
correlation, meaning that a higher methylation level was
associated with higher expression. Viewed in relation to
functional regions in genes, 70% of the positive correlations between methylation level and expression were
found in the 3’ UTR or the gene body. Similar findings
have been reported in chronic lymphocytic leukemia
[25] and support that promoter hypermethylation is an

important mechanism for gene silencing, while DNA
methylation elsewhere may have more complex functions
that are yet to be fully understood. Possible mechanisms
for regulation of gene expression by non-promoter methylation include interplay between nucleosome positioning
and chromatin structure, regulation of enhancer region
availability, and/or gene body regulation of alternative
promoters [25,26]. Statistical significance of correlation
between DNA methylation and gene expression was corrected for multiple testing by Bonferroni correction. This
method is very strict, and may underestimate the association between DNA methylation and gene expression.
The survival signature segregated patients with DCIS
and mixed DCIS-IBC into two groups with significantly
different prognosis. The signature classified most of the
patients with mixed DCIS-IBC that experienced breast
cancer-specific death into the bad prognosis group. Additionally, the single patient with pure DCIS that experienced breast cancer-specific death was also classified
into the bad prognosis group. Since only one of the patients with pure DCIS died of breast cancer, it was not
possible to perform the analysis on only patients with
pure DCIS. Taken together, the signature may have great
potential to classify patients with DCIS or mixed lesions
according to prognosis, but more patients must be studied to further validate the clinical value.
Several of the genes in the survival signature have roles
in tumor suppressive functions. The protein product of
IRF6 has been shown to function synergistically with the
tumor suppressor maspin to regulate mammary epithelial
differentiation [27], and has also been shown to have
tumor suppressor activity in squamous cell carcinoma [28].
TBX5 is a transcription factor that has been implicated as a
tumor suppressor in colon cancer and has been found
silenced by DNA methylation [29]. A SNP (rs1265507)
located between TBX5 and TBX3 was also associated
with mammographic density in a genome-wide association
study [30]. In the present study, high methylation levels of
CpGs in TBX5 were associated with lower expression
levels of TBX5 and adverse prognosis. DIEXF is thought to
be involved in the turnover of p53 [31], and CEND1 has
been shown to affect cyclin D1 levels [32]. ZNF259 has
been shown to be involved in regulation of the cell cycle
through interactions with the epidermal growth factor
receptor [33], and KCTD21 is thought to act as a tumor
suppressor in medulloblastoma by modulating Hedgehog signaling through degradation of histone deacetylase 1 [34].
Some genes in the survival signature have also been
associated with functions related to motility and invasion: EPN3 over-expression has been shown to promote
cancer cell invasion [35], MACF1 has been shown to be
involved in cell mobility and steering by interactions
with HER2 [36], and CSNK1G2 is thought to modulate
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the activity of metastasis-associated MTA1 while itself a
target of ER [37]. Taken together, many of the genes associated with the survival signature have tumor suppressive functions or are involved in regulation of motility
and ability to invade.
A strong immune component in breast tumors observed by measuring DNA methylation has previously
been reported [38]. The genes that were differentially
methylated between DCIS and IBC were borderline significantly enriched in the agranulocyte and granulocyte
adhesion and diapedesis pathways, suggesting that many
of the observed changes may occur in infiltrating cells or
in genes that enable cross-talk to such cells.
CUL7 (cullin 7) methylation levels increased from both
normal to DCIS and DCIS to IBC. CUL7 encodes a ubiquitin ligase that forms complexes with p53 and Parc. It
was shown to regulate apoptosis independently of p53
[39]. In another report [40], CUL7 was shown to function
as an antiapoptotic oncogene through cooperation with
Myc in a p53-dependent manner. Also, CUL7 has been
shown to be involved in liver carcinogenesis [41]. Importantly, CUL7 has not previously been reported in breast
cancer. ICAM2 (Intercellular adhesion molecule 2) methylation levels decreased between normal and DCIS, and increased between DCIS and IBC. ICAM2 is involved in cell
adhesion and thought to play a role in immune response.
In pancreatic cancer, ICAM2 has been reported to have
tumor suppressor function through immune surveillance [42].

Conclusion
DNA methylation profiles of DCIS were radically changed compared with normal breast tissue while the
changes between DCIS and IBC were comparably modest. A DNA methylation-based prognostic signature was
reported that has potential in patients both with invasive
breast cancer and with in situ carcinoma. Correlation
between DNA methylation and gene expression was observed in a substantial part of the genome, and both
positive and negative correlations were observed.
Materials and methods
Patient material

Material for this study was obtained from 285 fresh frozen
tissue samples representing different progression stages of
breast cancer; 46 normal samples, 22 pure DCIS, 31 mixed
DCIS-IBC and 186 pure IBC were included. Of the 46 normal samples, 17 were tissue from mammoplastic reductions
of healthy women collected at Akershus University Hospital
(institutional review board (IRB) approval number 429–
04148). Twenty-nine needle biopsies from healthy women
and 49 IBC samples were collected at the Norwegian Radium Hospital (IRB approval number S-02036) [43]. DCIS
samples, mixed DCIS-IBC samples, and 15 of the IBC
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samples were collected at Uppsala Academic Hospital (IRB
approval number Dnr 2005:118) [44,45]. Of the pure DCIS
samples, 18 of 22 had a tumor component of >75% [44].
The 123 IBC samples were collected from hospitals in the
Oslo region (IRB approval number S-97103) [46]. The IBC
samples were predominantly stage I and II. All studies are
in compliance with the Helsinki Declaration and were approved by local ethical committees and local authorities.
DNA methylation analysis

The DNA methylation status of more than 450,000 CpG
sites was interrogated using Illumina Infinium HumanMethylation450 microarray. The returned value of each
CpG probe is called β and is calculated as the methylated signal divided by the sum of the methylated and the
unmethylated signal. β thus represents the fraction of
methylated DNA molecules at a specific locus.
Preprocessing of DNA methylation data

Preprocessing and normalization involved steps of probe
filtering, color bias correction, background subtraction
and subset quantile normalization as previously described
[47]. After preprocessing of the data, 468,424 CpG probes
were included. The normalized data as well as the raw
data are available in Gene Expression Omnibus (GEO)
with accession number GSE60185.
Gene expression analysis

mRNA expression data were available for a subset of 104
of the IBC samples studied here. An Agilent whole genome 4x44K oligo array was used for the mRNA analysis as
previously described [48]. The mRNA expression data are
available in GEO with accession number GSE19783. Molecular subtypes of breast cancer (luminal A, luminal B,
HER2-enriched, basal-like and normal-like) were determined using the PAM50 gene list.
Methylation data processing

Statistical and bioinformatical analyses of the methylation level of the 285 samples were performed on two individual datasets, one including methylation levels of all
468,424 CpGs, and one including only 'gene region collapsed' data. The 'gene region collapsed' methylation
data were constructed to reduce the dimensions of the
methylation data and to focus the analysis on regions
that are most relevant for gene function. A CpG that is
mapped to a gene is located in one of six subregions:
TSS1500, TSS200, 5’ UTR, first exon, body and 3’ UTR.
These subregions represent: 1) CpGs that are between
1,500 and 200 bp upstream of the TSS; 2) CpGs that are
between 200 bp upstream of the TSS and the TSS itself;
3) CpGs in the 5’ UTR; 4) CpGs in the first exon; 5)
CpGs in other exons or in introns (body); and 6) CpGs
in the 3’ UTR. Methylation levels for each subregion
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were summarized using the median. In this approach
intergenic CpGs will not be included. The resulting gene
region collapsed dataset had 88,909 targets.
Methylation changes during progression of breast cancer

SAM was used to identify differentially methylated loci
between normal and DCIS, and between DCIS and IBC.
The analysis was performed using the SAM function of
the R package samr [49] with 100 permutations. For a
locus to be considered differentially methylated, the difference between the median methylation levels in the
two groups had to be at least 0.1 (10%) and the FDR qvalue had to be smaller than 0.01 (1%).
Hierarchical clustering

Hierarchical clustering was performed using the methylation level of the 500 most variable gene regions. The
distance matrix was calculated using Pearson correlation
and average linkage was applied.
Correlation between DNA methylation and gene
expression

Correlation between DNA methylation level and gene expression was investigated by two approaches. First, if a
CpG was within 100 kb of the TSS of a gene, the methylation level of the CpG and expression of the gene were
tested for non-zero correlation using Pearson correlation
(eMap1 function in the R package eMap) [50]. For both
analyses an association was considered significant if the
Bonferroni corrected P-value was smaller than 0.05.
Genome-wide correlation between methylation and expression was visualized using the R package quantsmooth
[51]. Second, the median methylation level of CpGs in the
'gene region collapsed' data and gene expression of the
corresponding gene was tested for non-zero correlation
using Pearson correlation (R function corr.test).
Survival analysis

Lasso regularization [52,53] was applied to identify
CpGs for which methylation level predicted survival (cv.
glmnet function in the R package glmnet) [54]. This approach gives a signature of targets that together capture
the variation that is associated with survival of patients.
Pre-selection was performed before regression in order
to reduce the number of possible CpG sites and to focus
on the ones correlated with expression. Univariate absolute correlation between methylation level and expression with nominal P-value lower than 0.05 were used to
preselect data, and 182,653 CpGs were included in the
analysis. The analysis was run 100 times and the probes
that were present in 80% of the resulting lists were used
in the final signature. The coefficients were calculated
as the mean of the coefficients in all lists where the
probe was present. Patients were divided into high- and
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low-risk groups according to the following index for
patient i:

indexi ¼

n
X

βg ⋅X g i

g¼1

where g is the target (CpG or gene), n is the number of
targets, βg is the Lasso coefficient for target g and Xgi is
the methylation value for target g in patient i. KaplanMeier estimator and log-rank tests were performed
using the functions Surv, survfit and survdiff (R package
survival) [55]. Breast cancer-specific survival was used in
all analyses.
Multivariate Cox proportional hazard survival analysis
was performed using the function coxph (R package survival) to adjust for ER status, TP53 mutation status, T
status and lymph node status. Each parameter in the
multivariate model was investigated for violations of the
assumption of proportional hazards using the function
cox.zph (R package survival).
Validation cohort of adjacent normal tissue and DCIS

To validate the methylation changes between normal tissue and DCIS, an independent set of DCIS and adjacent
normal tissues was profiled using the Illumina Infinium
HumanMethylation450 array. FFPE pure DCIS (n = 40)
and adjacent normal tissue (n = 15) underwent pathology
review and 2 mm core punches were taken for processing
as described in the Illumina Infinium FFPE Restoration solution protocol. The methylation data were preprocessed
using the R package ChAMP [56] and 397,600 probes out
of 485,577 remained after quality control. A gene region
collapsed data set was also constructed for this data set as
described above.
Validation cohort from The Cancer Genome Atlas

To validate the prognostic signature, DNA methylation
data and clinical information were downloaded from
TCGA data portal [9]. Only breast cancer patients for
whom there were both overall survival data and tumor
DNA methylation analysis had been performed by Illumina
HumanMethylation450 were used for validation (n = 583).
Probes with more than 50% missing values were removed,
and further missing values were imputed using the function pamr.knnimpute (R package pamr) [57] with k = 10.
Data analysis

All analyses were performed using the R computing framework [58]. Gene lists were analyzed with Ingenuity Pathways Analysis (Ingenuity® Systems, Redwood, California,
USA).
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Additional files
Additional file 1: Significance Analysis of Microarrays (SAM)
analysis of methylation level of gene regions between the five
PAM50 derived subtypes. Gene region, false discovery rate (FDR)
q-value and median methylation for each PAM50 subtype.
Additional file 2: Hierarchical clustering and heatmap of invasive
tumors using gene regions differentially methylated between the
five gene expression-derived subtypes.
Additional file 3: Correlation between DNA methylation and gene
expression; individual CpGs. Illumina probe ID, gene, transcription start
site (TSS), chromosome, position of CpG, CpG position relative to CpG
islands (CGIs) and gene region, correlation coefficient and uncorrected
P-value.
Additional file 4: Correlation between DNA methylation and gene
expression; functional gene regions. Gene, gene region (whose
methylation level correlates with expression), correlation coefficient and
uncorrected P-value.
Additional file 5: SAM analysis of methylation level of individual
CpGs between healthy breast tissue and DCIS. Illumina probe ID,
gene, CpG position relative to CGIs and gene region. Analyses performed
in two independent datasets. Only concordant results in both datasets
are reported.
Additional file 6: SAM analysis of methylation level of individual
CpGs between DCIS and IBC. Illumina probe ID, gene, CpG position
relative to CGIs and gene region.
Additional file 7: SAM analysis of methylation level of gene regions
between healthy breast tissue and DCIS. Analyses performed in two
independent datasets. Only concordant results in both datasets are
reported.
Additional file 8: SAM analysis of methylation level of gene regions
between DCIS and IBC.
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